ELOX Insider Trading Activity and SEC Form 4 Filings
ELOX insider trading summary
No open-market insider purchases or sales of Eloxx Pharmaceuticals, Inc. (ELOX) have been reported on SEC Form 4 in the past 12 months.
Latest ELOX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 29, 2021 | Daniel E. Geffken | Interim CFO | Buy | $36K (50,000 @ $0.72) |
| May 13, 2021 | Tomer Kariv | Director | Buy | $800K (592,592 @ $1.35) |
| May 13, 2021 | Tomer Kariv | Director | Buy | $1.7M (1,280,624 @ $1.35) |
| May 13, 2021 | Ran Nussbaum | Director | Buy | $3.6M (2,630,487 @ $1.35) |
| May 13, 2021 | Ran Nussbaum | Director | Buy | $800K (592,592 @ $1.35) |
| May 13, 2021 | Rajesh B Parekh | Director | Buy | $3.2M (2,381,890 @ $1.35) |
| May 13, 2021 | Tomer Kariv | Director | Buy | $1.9M (1,422,222 @ $1.35) |
| May 13, 2021 | Ran Nussbaum | Director | Buy | $1.7M (1,280,624 @ $1.35) |
| May 13, 2021 | Ran Nussbaum | Director | Buy | $1.9M (1,422,222 @ $1.35) |
| May 13, 2021 | Rajesh B Parekh | Director | Buy | $114K (84,776 @ $1.35) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.